Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease.
Alan D MichelsonE Smolensky KoganovE E FordeS L CarmichaelAndrew L FrelingerPublished in: Journal of thrombosis and haemostasis : JTH (2018)
In this randomized, double-blind, placebo-controlled, parallel-group study of CLD patients with thrombocytopenia, avatrombopag increased platelet counts but did not increase platelet activation in vivo or platelet reactivity in vitro.